This article was written by Follow Vasily Zyryanov is an individual investor and writer.He uses various techniques to find both relatively underpriced equities with...
This article was written by Follow David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As...
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds and exchange-traded...
Overview Automation, Robotics and Artificial Intelligence are keywords, concepts and megatrends that stoke greed and fear in many an investor heart. However, why are...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is developing JNJ-2113 (PN-235), an oral IL-23 drug targeting psoriasis, however partner Johnson & Johnson (JNJ) says that until the...
The Biden administration has so far approved over $22 billion in student loan forgiveness for borrowers who were harmed by school misconduct. And the...